OPTIMIZERx Corporation Announces SampleMD(TM) Q1 2013 Operational Update
16 April 2013 - 4:44PM
Marketwired
Today OPTIMIZERx Corporation (OTCQB: OPRX) announced the
preliminary results of SampleMD's eCoupon and eVoucher
distributions from January 1st, 2013 through March 28th, 2013. The
Company reported that from January 1st, 2013 through March 28th
2013, SampleMD generated over 177,000 new ePrescriptions with
Co-Pay Coupons or Free Sample Voucher to help patients more
affordably start and stay on their prescribed medications.
The Company's CEO Mr. Shad Stastney stated, "Although the
absolute number of new prescriptions written with one of our
promoted electronic Co-Pay or Voucher programs is impressive in
itself, the trend line within the quarter is also very encouraging
-- in March alone we distributed over 85,000 patient coupons in
total. We look forward to increasing our ability to generate more
prescriptions for our pharmaceutical clients; increasing our
revenue contributions to our ePrescribing and EHR partners; and
most importantly, improving adherence and outcomes for health care
providers and their patients."
The total savings distributed included 38,000 co-pay coupons
distributed by SampleMD from a legacy program with an ePrescribe
platform partner.
For more information, please go to www.optimizerxcorp.com or
contact us at 248-651-6568.
About OPTIMIZERx Corp. OPTIMIZERx Corp. provides unique consumer
and physician platforms to help patients better afford and comply
with their medicines and healthcare products, while offering
pharmaceutical and healthcare companies effective ways to expand
patient awareness, access and adherence to their medications. For
more information, please go to www.optimizerxcorp.com or
www.samplemd.com. SampleMD is a software as a service application
that automates the drug industries $5 billion sample issuance
process, so care providers can now provide co-pay discount coupons
and free sample & vouchers to patients right from within their
doctor's eprescribe or electronic health record workflow.
This press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended and such section 21E of the Securities Act
of 1934, amended. These forward-looking statements should not be
used to make an investment decision. The words 'estimate,'
'possible' and 'seeking' and similar expressions identify
forward-looking statements, which speak only as to the date the
statement was made. The company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material
risks.
Company contact: Mr. Shad Stastney CEO 248-651-6568 Email
Contact
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024